MANSFIELD, MA, January 10, 2023 — Hilltop BioSciences, a veterinary biotech company pioneering the development of innovative regenerative therapies, will be introducing several new formulations at VMX in Orlando where they will be showcased in the Startup Circle (Booth s5027).
Already established in the equine arena, Regenaflex stimulates cell-to-cell communication that is essential for healing soft tissue by delivering an intracellular, cell-signaling cascade of cytokines, microRNA, growth factors and exosomes to the affected area. (Read more about the active components in Hilltop Bio’s products).
“Regenaflex has significant potential in the companion animal marketplace,” says Hilltop Bio Chief Executive Officer Amanda Drobnis. “We look forward to introducing our innovative regenerative products at VMX.”
Regenaflex can be reconstituted and ready to use in under a minute. Unlike other biologics, such as platelet-rich plasma (PRP), stem cell, and conditioned serum products, Hilltop Bio’s products offer long-term room-temperature storage, have consistent composition in every dose, require no special equipment or time-consuming processing, and are formulated to target specific indications.
The three new formulations include:
- Regenaflex-K9 – An advanced regenerative soft tissue therapy tailored for practical application in veterinary practices. It establishes normal tissue functionality in treating acute trauma, chronic infections, and inflammation, nonhealing wounds, anal gland abscesses and fistulae.
- Regenaflex-M Biofilm – A clinically proven anti-inflammatory, antimicrobial, and anti-adhesion scaffold formulation that accelerates tissue healing. Literature has shown, the Biofilm minimizes scar tissue formation without development of postoperative adhesions following abdominal or orthopedic surgery. It has also been shown to prevent postoperative suture leakage following intestinal anastomosis or cystotomy.
- PureOptic – Easy-to-use eye drops that include the same power-packed regenerative cargo as Hilltop’s other products and literature has shown can be used to normalize damaged tissue resulting from eye injuries or disease.
According to Heather Sherman, DVM,
“This was kind of a slam dunk case. There was no negative reaction to [Regenaflex] and the leg responded better than I would’ve expected given the animal’s age and the absence of any adjunctive therapies.”
[Hear more from Dr Sherman about this case]
Veterinarians interested in participating in Hilltop Bio’s planned clinical trials should inquire about enrolling their patients.
